OBM Genetics is an international Open Access journal published quarterly online by LIDSEN Publishing Inc. It accepts papers addressing basic and medical aspects of genetics and epigenetics and also ethical, legal and social issues. Coverage includes clinical, developmental, diagnostic, evolutionary, genomic, mitochondrial, molecular, oncological, population and reproductive aspects. It publishes research articles, reviews, communications and technical notes, etc. There is no restriction on the length of the papers and we encourage scientists to publish their results in as much detail as possible.

Archiving: full-text archived in CLOCKSS.

Rapid publication: manuscripts are undertaken in 8.5 days from acceptance to publication (median values for papers published in this journal in the first half of 2019, 1-2 days of FREE language polishing time is also included in this period).

Free Publication in 2019
Current Issue: 2019  Archive: 2018 2017

Special Issue

Alternative Splicing: A Key Process in Development and Disease

Submission Deadline: December 31, 2019 (Open)                Submit Now

Guest Editor

Michael R. Ladomery, PhD
Faculty of Health and Applied Sciences, University of the West of England, Bristol; Frenchay Campus,
Coldharbour Lane, Bristol BS16 1QY, UK
E-Mail: Michael.Ladomery@uwe.ac.uk
Website: http://www.ladomerylab.org
Research Interests: RNA biology; alternative splicing; noncoding RNA; RNA-based cancer therapies

About this topic

Soon after the discovery of pre-mRNA splicing in the late 1970s it became apparent that transcripts can be ‘alternatively spliced’ across eukaryotes. The main modes of alternative splicing are cassette exons that can be skipped; alternative splice sites that change the boundaries of exons; mutually exclusive exons; and retained introns. It is thought that over 94% of multi-exonic genes are alternatively spliced in humans. Alternative splicing is affected by regulatory sequences present within exons and introns. These are recognised by a multitude of splice factors that regulate splicing machinery access. Alternative splicing means that genes can express proteins with strikingly different characteristics. These can even have antagonistic properties (for example pro- or anti-apoptotic splice isoforms). It is then not surprising to find that alternative splicing plays a key role in development and that mutations that disrupt alternative splicing contribute to disease. Alternative splicing research provides enormous opportunities to understand fundamental biological processes; it also presents a new context in which to develop novel therapies.

Planned Papers

Title: Alternative splicing in neuroendocrine prostate cancer
Author: Jennifer Munkley

Title: Alternative splicing during activation of immunoglobulin class switching in human B cells
Author: Youming Zhang

Title: Environmentally induced alternative splicing
Author: Fatima Smagulova

Title: Splicing mRNAs in cytoplasm: the HAC1/XBP1 mRNA splicing pathway in the unfolded protein response
Author: Weihan Li

Newsletter

TOP